This document comprises a legal declaration filed in the United States District Court for the District of Massachusetts, related to a case involving Janssen Biotech, Inc., New York University, Celltrion Healthcare Co., Ltd., Celltrion, Inc., and Hospira, Inc. The declaration, made by attorney Dan H. Hoang, supports defendants' motions for partial summary judgment and preliminary/permanent injunction, as well as their cross-motion for partial summary judgment.
The filing also includes several exhibits, notably Exhibit 5, which is a transcript of a Congressional hearing. This hearing, titled "Biologics and Biosimilars: Balancing Incentives for Innovation," was held on July 14, 2009, before the Subcommittee on Courts and Competition Policy of the House Committee on the Judiciary.
The hearing transcript details discussions and testimonies concerning the landscape of biologics and biosimilars, aiming to balance innovation incentives within the industry. It features opening statements from committee members and oral and prepared testimonies from various stakeholders, including representatives from pharmaceutical companies, research institutions, and industry organizations.
The document is part of a legal proceeding and provides context through the referenced hearing on regulatory and economic aspects of biopharmaceutical development.
